The use of Waklert 150 is primarily related to the enhancement of wakefulness with regard to certain types of sleep disorders. Waklert 150 has armodafinil 150 mg as its active ingredient, a wakefulness agent. According to Australian product information, armodafinil can be used as therapy for excessive daytime sleepiness linked with narcolepsy, a disorder characterized by an individual's tendency to fall asleep abnormally during normal awake periods. Armodafinil can also be used as therapy for excessive sleepiness due to chronic shift work sleep disorder (SWSD) from moderate to severe intensity where non-pharmacological measures cannot prove to be effective. Additionally, excessive sleepiness linked with obstructive sleep apnoea/hypopnoea syndrome (OSAHS) has been recognized as one of the uses of armodafinil as a complement to CPAP in enhancing wakefulness in patients. Armodafinil does not cure the airway obstruction itself. The mechanism of action of armodafinil involves acting on the central nervous system to promote wakefulness; however, it is not completely known yet. The recommended dose of armodafinil in Australian information is 150 mg for SWSD while 150 mg and 250 mg doses can be used once daily for narcolepsy and OSAHS respectively.

https://www.genericmedsaustralia.com.au/products/waklert-150-australia/